We found that CXCR3 pathway activation can not only predict the effectiveness of ICIs in patients with metastatic urothelial carcinoma, but it can also predict the effectiveness of immunotherapy in patients with melanoma, non-small cell lung cancer, and liver cancer. The gene discussed is CXCR3; the disease is liver cancer.